Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
To help diagnose tuberculosis (TB) and infections caused by other Mycobacterium species, which are known as acid-fast bacilli (AFB), in people at risk of developing mycobacterial infections; to monitor the effectiveness of treatment
When you have signs and symptoms of a lung infection, such as a chronic cough, weight loss, fever, chills, and weakness, that may be due to TB or a nontuberculous mycobacterial (NTM) infection; when you have a positive IGRA blood test or Tuberculin skin test (TST) and you are in a high-risk group for progressing to active TB; when you have a skin or other body site infection that may be due to mycobacteria; when you are undergoing treatment for TB
For suspected cases of tuberculosis lung infections, usually three sputum samples are collected early in the morning on different days. If you are unable to produce sputum, a bronchoscope may be used to collect fluid during a procedure called a bronchoscopy. In children, gastric washings/aspirates may be collected. Depending on symptoms, urine, an aspirate from the site of suspected infection, cerebrospinal fluid (CSF), other body fluids, or biopsied tissue samples may be collected for AFB testing.
Most samples that are submitted for acid-fast bacilli (AFB) testing are collected because the healthcare practitioner suspects that a person has tuberculosis (TB), a lung infection caused by Mycobacterium tuberculosis. Mycobacteria are called acid-fast bacilli because they are a group of rod-shaped bacteria (bacilli) that can be seen under the microscope following a staining procedure where the bacteria retain the color of the stain after an acid wash (acid-fast). AFB laboratory tests detect the bacteria in a person's sample and help identify an infection caused by AFB.
There are several types of AFB that may be detected with this testing; however, the most common and medically important ones are members of the genus Mycobacterium. Mycobacterium tuberculosis is one of the most prevalent and infectious species of mycobacteria.
Since TB is transmitted through the air when an infected person sneezes, coughs, speaks, or sings, it is a public health risk. It can spread in confined populations, such as in the home and schools, correctional facilities, and nursing homes. Those who are very young, elderly, or have preexisting diseases and conditions, such as AIDS, that compromise their immune systems tend to be especially vulnerable. AFB testing can help diagnose, track, and minimize the spread of TB in these populations and help determine the effectiveness of treatment.
Another group of mycobacteria referred to as nontuberculous mycobacteria (NTM) can also cause infections. However, only a few of the more than 60 species of mycobacteria that have been identified cause infections in humans. Some examples include Mycobacterium avium-intracellulare complex (MAC), which can cause lung infection and disseminated disease in people with weakened immune systems. (See the article on Nontuberculous Mycobacteria for more details on different types). In addition to TB, AFB testing can help identify infections caused by these nontuberculous mycobacteria.
See "How is it used?" under Common Questions below for details on AFB tests.
How is the sample collected for testing?
Sputum is the most commonly tested sample. Sputum is phlegm, thick mucus that is coughed up from the lungs. Preferably, three early morning samples obtained by deep cough are collected on consecutive days in individual sterile cups to increase the likelihood of detecting the bacteria.
If a person is unable to produce sputum, a healthcare practitioner may collect respiratory samples using a procedure called a bronchoscopy. Bronchoscopy allows the healthcare practitioner to look at and collect samples from the bronchi and bronchioles. Once a local anesthetic has been sprayed onto the patient's upper airway, the practitioner can insert a tube into the bronchi and smaller bronchioles and aspirate fluid samples for testing. Sometimes, the healthcare practitioner will introduce a small amount of saline through the tubing and into the bronchi and then aspirate it to collect a bronchial washing.
Since young children cannot produce a sputum sample, gastric washings/aspirates may be collected. This involves introducing saline into the stomach through a tube, followed by fluid aspiration.
If the healthcare practitioners suspect TB is present outside of the lungs (extrapulmonary), they may test the body fluids and tissues most likely affected. For instance, one or more urine samples may be collected if the practitioner suspects TB has infected the kidneys. A needle may be used to collect fluid from joints or from other body cavities, such as the pericardium or abdomen. Occasionally, the practitioner may collect a sample of cerebrospinal fluid (CSF) or perform a minor surgical procedure to obtain a tissue biopsy.
Is any test preparation needed to ensure the quality of the sample?
No test preparation is needed, except to rinse the mouth with water before collecting the sputum sample.
AFB testing may be used to detect several different types of acid-fast bacilli, but it is most commonly used to identify an active tuberculosis (TB) infection.
Mycobacteria are called acid-fast bacilli because they are rod-shaped bacteria (bacilli) that can be seen under the microscope following a staining procedure in which the bacteria retain the color of the stain after an acid wash (acid-fast).
A few different tests may be used to help identify AFB as the cause of an infection:
AFB testing is ordered when:
AFB Smear and NAAT
A negative AFB smear may mean that no infection is present, that symptoms are caused by something other than mycobacteria, or that the mycobacteria were not present in sufficient numbers to be seen under the microscope. Usually three samples are collected to increase the probability that the organisms will be detected.
Nevertheless, if AFB smears are negative and there is still a strong suspicion of a mycobacterial infection, then additional samples may be collected and tested on different days. A smear negative sample may still grow mycobacteria since the culture media allows low numbers of bacteria that cannot be seen in a microscopic examination to multiply and be detected.
Positive AFB smears indicate a probable mycobacterial infection. However, a culture must be performed to confirm a diagnosis and identify the species of mycobacteria present.
For people with signs and symptoms of an active TB infection, AFB smear results are considered together with results from NAAT for TB, as recommended by the Centers for Disease Control and Prevention. Though definitive diagnosis requires results from a culture, results from the smear and NAAT may be helpful in deciding what to do. For example, if there is a presumptive diagnosis of TB based on rapid test results, most health practitioners would treat.
Interpretation of smear and NAAT results are summarized in the following table. Again, all results must be confirmed by results from culture.
|AFB smear result||NAAT result for TB||Interpretation|
|Positive||Positive||Presumptive diagnosis for TB|
|Negative||Positive||NAAT is more sensitive than an AFB smear so this may occur in people with true disease; may test additional samples using NAAT. If more than one sample is positive by NAAT, this is a presumptive diagnosis for TB.|
|Positive||Negative||Questionable results for TB; the AFB seen on the smear are not M. tuberculosis.|
|Negative||Negative||Symptoms probably not due to active mycobacterial infection.|
Positive AFB cultures identify the particular mycobacterium causing symptoms, and susceptibility testing on the identified organism gives the healthcare practitioner information about how resistant it may be to treatment.
A positive AFB smear or culture several weeks after drug treatment has started may mean that the treatment regimen is not effective and needs to be changed. It also means that the person is still likely to be infectious and can pass the mycobacteria to others through coughing or sneezing.
A negative culture means that the person tested does not have an active AFB infection or that mycobacteria were not present in that particular sample (which is why multiple samples are often collected) or were present in numbers too low to be detected. Cultures are held for six to eight weeks before being reported as negative. The person tested may have a latent infection that caused a TB screening test to be positive but does not have active TB.
If it is suspected that someone has a TB infection that has spread to another part of the body, a sample from the site of suspected infection may need to be collected and tested to identify the infection.
A negative culture several weeks after treatment indicates that the TB infection is responding to drug treatment and that the person is no longer infectious.
Susceptibility testing results will list the antibiotics that will likely be most effective in treating the infection. Isoniazid and rifampin are two drugs commonly used to treat TB. If the bacteria are resistant to more than one or the primary drugs used for therapy, the organisms are called multidrug-resistant TB (MDR-TB), and if the organisms are resistant to multiple drugs approved for first and second lines of therapy, they are called extensively drug-resistant tuberculosis (XDR-TB).
TB requires a lengthy course of multiple antibiotics to cure an active infection. People with inactive (latent) infections, although asymptomatic, may be treated with a single drug to reduce the risk of having an active infection in the future.
A faster lab method to culture Mycobacterium tuberculosis has been developed. Culturing the sample in a liquid broth-based medium allows the organisms to be detected sooner. Some of the broth cultures require an automated instrument to detect the presence of the mycobacteria, while other methods can be read manually. A liquid culture method, called Microscopic-Observation Drug-Susceptibility (MODS) assay, takes only about 7 days to diagnose TB and detects bacterial resistance to antibiotics at the same time. Since this method can recognize the presence of multidrug-resistant TB (MDR-TB) much more quickly than conventional culture, it can help health practitioners diagnose and treat the disease at an earlier stage and has the potential to help control the spread of infectious TB. The benefits and limitations of this non-automated test are still being evaluated in resource-limited countries with high prevalence of TB.
There are other new methods being used in some laboratories that can identify M. tuberculosis very rapidly and accurately once the mycobacteria is growing in culture.
Yes. There are many people in the United States and worldwide who have a latent form of TB infection. They have been exposed to the bacteria, but their body's immune system has confined it to a localized area in their lungs, in an inactive form. People with latent TB infections are not sick and they are not infectious, but the bacteria are still there and still alive. If those with latent infections are tested, most would have a positive TB skin test or IGRA test. The majority of people with latent TB infection, about 90%, will never progress to active tuberculosis disease.
Those who do have active TB may not feel ill at first. Early symptoms may be subtle and, if the TB is extrapulmonary (outside of the lungs in organs such as the kidney and bone), the tuberculosis may be fairly advanced by the time it causes noticeable symptoms.
Both indicate strains of Mycobacteria tuberculosis that can be difficult to treat, but XDR-TB is resistant to more drug therapies. MDR-TB is resistant to the two most powerful drugs, isoniazid and rifampin. XDR-TB is currently defined by the Centers for Disease Control and Prevention and the World Health Organization as M. tuberculosis that is resistant to isoniazid and rifampin plus resistant to any fluoroquinolone and to at least one of three injectable "second-line" drugs (amikacin, kanamycin, or capreomycin). The emergence of XDR-TB represents a public health risk and is being closely watched by the world medical community and measures are being taken in hopes of limiting its spread.
The practice of taking TB medications in the presence of a healthcare practitioner is known as direct observed therapy (DOT). DOT ensures that people are taking their medications and continuing their therapy for the required length of time. Unlike other bacterial infections that can be cured in 7-10 days, TB must be treated with two or more drugs for several months. People tend to forget to take their medication when they are feeling better. Since TB medications must be taken for many months, the risk of non-compliance is high. Having a healthcare practitioner administer the medications weekly increases the likelihood that the entire regimen will be completed and decreases the likelihood that someone will relapse with a more resistant strain of TB.
Examples of other mycobacteria that can cause infections and are detected using AFB tests include:
See the article on Nontuberculous Mycobacteria for more examples and details.
Nocardia species are not a type of mycobacteria but can be detected using some AFB laboratory tests. Nocardia can cause infections of the lungs, brain, or skin.
Sources Used in Current Review
Lewinsohn, D, et. al. (2017 January 03). Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases, Volume 64, Issue 2, 15 January 2017, Pages 111–115. Available online at https://academic.oup.com/cid/article/64/2/111/2811357. Accessed on 8/05/18.
Vyas, J. et. al. (2016 November 14, Updated). Sputum stain for mycobacteria. MedlinePlus Medical Encyclopedia. Available online at https://medlineplus.gov/ency/article/003724.htm. Accessed on 8/05/18.
Koirala, J. (2017 November 14, Updated). Mycobacterium Avium Complex (MAC) (Mycobacterium Avium-Intracellulare [MAI]). Medscape Infectious Diseases. Available online at https://emedicine.medscape.com/article/222664-overview. Accessed on 8/05/18.
Herchline, T. and Amorosa, J. (2017 November 9, Updated). Tuberculosis (TB). Medscape Infectious Diseases. Available online at https://emedicine.medscape.com/article/230802-overview. Accessed on 8/05/18.
Batra, V. and Ang, J. (2018 April 26, Updated). Pediatric Tuberculosis. Medscape Pediatrics: General Medicine. Available online at https://emedicine.medscape.com/article/969401-overview. Accessed on 8/05/18.
Barker, A. (2018 July, Updated). Mycobacterium tuberculosis – Tuberculosis. ARUP Consult. Available online at https://arupconsult.com/content/mycobacterium-tuberculosis. Accessed on 8/05/18.
Sources Used in Previous Reviews
Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].
Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.
Heimerdinger, M. (2000). Tuberculosis. ACP-ASIM [On-line session report]. Available online at http://www.acponline.org/vas2000/sessions/tb.htm.
Kirchner, J. (2000 February 1). Do Sputum Smears Positive for AFB Signify Treatment Failure? American Family Physician [On-line journal]. Available online at http://www.aafp.org/afp/20000201/tips/25.html.
Jerant, A. et.al. (2000 May 1). Identification and Management of Tuberculosis. American Family Physician [On-line journal]. Available online at http://www.aafp.org/afp/20000501/2667.html.
Sadovsky, R. (2001 May 15). Making the Diagnosis of Tuberculosis in Children. American Family Physician [On-line journal]. Available online at http://www.aafp.org/afp/20010515/tips/9.html.
Centers for Disease Control and Prevention (2002 August 13, Reviewed). Frequently Asked Questions, Questions and Answers about TB. National Center for HIV, STD and TB Prevention Division of Tuberculosis Elimination [On-line information]. Available online at http://www.cdc.gov/nchstp/tb/faqs/qa.htm.
Tuberculosis. The Merck Manual of Medical Information--Home Edition [On-line information]. Available online at http://www.merck.com/pubs/mmanual_home/sec17/181.htm.
Tan, L.J. (2000 June 28, Updated). ATS/CDC Statement Revises Treatment and Testing for Latent TB Infection. American Medical Association [On-line information]. Available online at http://www.ama-assn.org/ama/pub/article/1865-2125.html.
Mazurek, G. & Villarino, M. (2002 December 18 Updated). Guidelines for Using the QuantiFERON®-TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report [On-line report]. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/di51cha1.htm.
Centers for Disease Control and Prevention (2002 March 23, Reviewed). TB and HIV Coinfection. National Center for HIV, STD and TB Prevention, Division of Tuberculosis Elimination [On-line information]. Available online at http://www.cdc.gov/nchstp/tb/pubs/TB_HIVcoinfection/default.htm.
Tuberculosis: Ancient Enemy Present Threat, "I must die": Tuberculosis in History. NAIAD [On-line information]. Available online at http://www.niaid.nih.gov/newsroom/focuson/tb02/story.htm.
Tuberculosis (TB). American Lung Association [On-line information]. Available online at http://www.lungusa.org/diseases/lungtb.html.
(2002 January). American Lung Association® Fact Sheet: Tuberculosis. ALA [On-line information]. Available online at http://www.lungusa.org/diseases/tbfac.html.
(2002 January). American Lung Association® Fact Sheet: Tuberculosis Skin Test. ALA [On-line information]. Available online at http://www.lungusa.org/diseases/tbskinfac.html.
(2002 January). American Lung Association® Fact Sheet: Pediatric Tuberculosis. ALA [On-line information]. Available online at http://www.lungusa.org/diseases/pedtbfac.html.
NIAID (1999 December 1, Updated). The Global Burden of Tuberculosis. National Institute of Allergy and Infectious Diseases, National Institutes of Health [On-line publication]. Available online at http://www.niaid.nih.gov/publications/blueprint/page2.htm.
Tuberculin skin test. Hendrick Health System AccessMed [On-line information]. Available online at http://www.hendrickhealth.org/healthy/00069330.html.
Tuberculosis. Hendrick Health System AccessMed [On-line information]. Available online at http://www.hendrickhealth.org/healthy/00069340.html.
Mycobacteriology, Introduction to the Genus Mycobacteria. Microbiology Public Health for Northern Alberta, Bugs on the Web [On-line information]. Available online at http://www2.provlab.ab.ca/bugs/mycob/mbintro.htm.
Mycobacteriology, Acid-Fast Staining Procedures for Mycobacteria. Microbiology Public Health for Northern Alberta, Bugs on the Web [On-line information]. Available online at http://www2.provlab.ab.ca/bugs/mycob/afb_stain/afb_tutorial.htm.
Hall, G. (2001). Practical Microbiology, Update on Broth Media for the Isolation of Mycobacterium Species. Medscape from Infect Med 18(1):28-30, 2001 [On-line journal]. Available FTP: http://www.medscape.com/viewarticle/410131.
Tuberculin Purified Protein Derivative (Mantoux) Tubersol. Aventis Pasteur Inc. (Swiftwater, PA) [Package Insert].
(1996 October 28, Rev L). AccuProbe, Mycobacterium Tuberculosis Complex Culture Identification Test. Gen-Probe [Package Insert]. Available online at http://www.gen-probe.com/mtd.html.
(2006 November 3). Notice to Readers: Revised Definition of Extensively Drug-Resistant Tuberculosis. CDC MMWR 55(43);1176 [On-line information]. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5543a4.htm. Accessed December 10, 2006.
(2006 April). Tuberculosis: General Information. National Center for HIV, STD, and TB Prevention, Division of Tuberculosis Elimination Fact Sheet [On-line information]. Available online at http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250010.htm. Accessed December 10, 2006.
(2006 March, Revised). Tuberculosis. World Health Organization [On-line information]. Available online at http://www.who.int/mediacentre/factsheets/fs104/en/index.html. Accessed December 10, 2006.
(2006 March). Tuberculosis. Accessed December 10, 2006. NIAID Fact Sheet [On-line information]. Available online at http://www.niaid.nih.gov/factsheets/tb.htm.
(2006 April). Diagnosis of Tuberculosis Disease. National Center for HIV, STD, and TB Prevention, Division of Tuberculosis Elimination Fact Sheet [On-line information]. Available online at http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250102.htm. Accessed December 10, 2006.
Pagana, Kathleen D. & Pagana, Timothy J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 955-957.
Moore, DAJ et al. Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB. New England Journal of Medicine 2006;355:1539-1550.
Forbes BA, Sahm DF, Weissfeld AS, Bailey & Scott's Diagnostic Microbiology 12th Edition: Mosby Elsevier, St. Louis, MO; 2007, Pp 478-508.
Centers for Disease Control and Prevention (July 1, 2010 Reviewed). Diagnosis of Tuberculous Disease. Available online at http://www.cdc.gov/tb/publications/factsheets/testing/diagnosis.htm. Accessed January 2011.
Centers for Disease Control and Prevention. Updated Guidelines for the use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis. MMWR January 16, 2009 / 58(01); 7-10. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?s_cid=mm5801a3_e. Accessed January 2011.
Herchline, T (December 17, 2010). Tuberculosis. eMedicine article. Available online at http://emedicine.medscape.com/article/230802-overview. Accessed January 2011.
(Jan. 29, 2009) Mayo Clinic. Tuberculosis. Available online at http://www.mayoclinic.com/health/tuberculosis/DS00372. Accessed January 2011.
(November 12, 2010) National Institute of Allergy and Infectious Diseases. Tuberculosis (TB). Available online at http://www.niaid.nih.gov/topics/tuberculosis/Pages/default.aspx. Accessed January 2011.
(November 2010) World Health Organization. Tuberculosis Fact Sheet. Available online at http://www.who.int/mediacentre/factsheets/fs104/en/index.html. Accessed January 2011.
Boehme C, et. al. Rapid Molecular Detection of Tuberculosis and Rifampin Resistance. N Engl J Med 2010; 363:1005-1015. Available online at http://www.nejm.org/doi/full/10.1056/NEJMoa0907847. Accessed January 2011.
Minion J, Leung E, Menzies D, Pai M. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Inf Dis, 2010 Oct;10(10):688-98. Epub 2010 Aug 31. Available online at http://www.ncbi.nlm.nih.gov/pubmed/20813587. Accessed January 2011.
Herchline, T. and Amorosa, J. (Updated 2014 June 9). Tuberculosis. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/230802-overview. Accessed August 2014.
(© 1995–2014). Acid-Fast Smear for Mycobacterium. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/8213. Accessed August 2014.
Koirala, J. (Updated 2014 March 14). Mycobacterium Avium-Intracellulare. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/222664-overview. Accessed May 2014.
Zieve, D. (Updated 2013 November 20). Acid-fast stain. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/003766.htm. Accessed August 2014.
(Updated 2014 May). Mycobacterium tuberculosis – TB. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/TB.html. Accessed August 2014.
Dugdale, D. (Updated 2011 December 6). Sputum stain for mycobacteria. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/003724.htm. Accessed August 2014.
Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 983-984.
Availability of an Assay for Detecting Mycobacterium tuberculosis, Including Rifampin-Resistant Strains, and Considerations for Its Use — United States, 2013. Morbidity and Mortality Weekly Report October 18, 2013 / 62(41);821-824. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6241a1.htm?s_cid=mm6241a1_e. Accessed Sept 2014.
Food and Drug Administrations News Release: FDA permits marketing of first U.S. test labeled for simultaneous detection of tuberculosis bacteria and resistance to the antibiotic rifampin. July 25, 2013. Available online http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm362602.htm. Accessed September 2014.
(February 11, 2014) Centers for Disease Control and Prevention. A New Tool to Diagnose Tuberculosis: The Xpert MTB/RIF Assay. Available online at http://www.cdc.gov/tb/publications/factsheets/testing/Xpert_MTB-RIF.htm. Accessed September 2014.